| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | QW-BI-011 | CTRPv2 | pan-cancer | AAC | 0.095 | 0.2 |
| mRNA | Vandetanib | FIMM | pan-cancer | AAC | 0.22 | 0.2 |
| mRNA | Doxorubicin | FIMM | pan-cancer | AAC | -0.19 | 0.2 |
| mRNA | VX-702 | GDSC1000 | pan-cancer | AAC | 0.047 | 0.2 |
| mRNA | Y-39983 | GDSC1000 | pan-cancer | AAC | 0.042 | 0.2 |
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | -0.057 | 0.2 |
| mRNA | GSK429286A | GDSC1000 | pan-cancer | AAC | 0.043 | 0.2 |
| mRNA | OSU-03012 | GDSC1000 | pan-cancer | AAC | 0.045 | 0.2 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | 0.045 | 0.2 |
| mRNA | L-685458 | CCLE | pan-cancer | AAC | 0.061 | 0.2 |